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CASE HISTORY: A 14-year-old neutered male Sealyham terrier was referred for assessment of a 
persistent pyoderma. It had experienced numerous episodes of dermatitis involving pododermatitis, 
pyoderma and otitis over the previous 6 years. 
CLINICAL FINDINGS: Superficial, focally deep and mucocutaneous pyoderma were present, with 
yellow mucoid exudate on both nares and the lower lips crusted with haemopurulent exudate. 
Epidermal collarettes were present on the dorsal and lateral trunk. There were peri-anal crusts and 
mild erythema was present on the concave aspect of both pinnae. 
MICROBIOLOGICAL FINDINGS: Culture and microbiological testing identified Staphylococcus 
pseudintermedius as the infecting organism. Kirby-Bauer disc susceptibility testing revealed the 
isolate was resistant to numerous antimicrobials including oxacillin. PCR testing of the isolate 
identified the presence of the mecA gene which confers resistance to β-lactam antimicrobials. Pulsed 
field gel electrophoresis typing suggested the isolate was not related to the methicillin-resistant S. 
pseudintermedius that had been reported to be associated with canine infections in Western Australia. 
DIAGNOSIS: Superficial, deep and mucus membrane pyoderma associated with a multi-drug 
resistant S. pseudintermedius. 
CLINICAL RELEVANCE: This is the first recorded case of canine pyoderma involving methicillin-
resistant multidrug-resistant S. pseudintermedius in New Zealand. Treatment of such cases is difficult 
because the number of effective and available antimicrobials is limited. This finding should raise the 
awareness of the veterinary and medical professions to the presence of such organisms in New 
Zealand and stimulate a discussion about possible biosecurity barriers, treatment strategies and 
prevention of zoonotic and nosocomial infections. 





Approximately 50% of healthy dogs are colonised by Staphlococcus pseudintermedius (Saijonmaa-
Koulumies and Lloyd 1995; Harvey and Noble 1998). Although primarily isolated from the oral, 
nasal and peri-anal regions, transient colonisation of other sites may occur. S. pseudintermedius is an 
opportunistic pathogen and may cause canine skin and ear infections. The S. pseudintermedius strain 
causing an infection is usually the same as the colonising strain (Pinchbeck et al. 2006). Antimicrobial 
treatment may include the use of oral and topical antimicrobials, and biocides. In New Zealand β-
lactam antimicrobials such as amoxicillin-clavulanic acid and cephalosporins are empirically used. 
Microbiological culture is reported to not be routinely performed for suspected canine pyoderma and 
is reserved for cases that respond poorly to antimicrobials or relapse frequently (Pleydell et al. 2012). 
Isolates of S. pseudintermedius resistant to methicillin were initially reported in the early to mid 2000s 
in the United States of America, Europe and Asia, and have subsequently become a significant 
problem in veterinary medicine (Frank and Loefffler 2012). Similar to methicillin resistance 
in Staphylococcus aureus, resistance in S. pseudintermedius is mediated by the production of a 
modified penicillin binding protein (PBP2a) which is produced by the mecA gene. MecA is located on 
a chromosomal mobile element called the staphylococcal chromosomal cassette which can be 
transferred between staphylococci (Harrison et al. 2014). Regional clonal spread of methicillin-
resistant S. pseudintermedius (MRSP) has been reported in several countries including Australia 
(Perreten et al. 2010; Siak et al. 2014). Globally, MRSP are usually resistant to multiple classes of 








A 14-year-old, castrated, Sealyham terrier dog, from the Waikato region of New Zealand had 
experienced numerous episodes of dermatitis involving pododermatitis, pyoderma and otitis over 6 
years, commencing prior to 2006. 
Dermatological investigations included food trials over 6–8 weeks using a hydrolysed diet. No change 
in pruritus resulted. Microbiological culture of an ear exudate in November 2011 
identified Staphylococcus intermedius group bacteria assumed to be S. pseudintermedius. The 
organism was resistant to neomycin, framycetin and oxacillin. Atopic dermatitis was thought to 
underlie the predisposition to pyoderma. 
Treatment of the skin and ear problems included 10 mg per day oral prednisone (Apo-Prednisone, 
Apotex NZ Ltd, Auckland, NZ) and antimicrobials; including 600 mg oral cephalexin twice daily, 625 
mg twice daily amoxycillin/clavulanate (Vetamox, Ethical agents, Auckland, NZ) and on one 
occasion 75 mg once daily oral enrofloxacin (Baytril, Bayer NZ Ltd, Auckland, NZ). Episodes of 
otitis were treated topically with antimicrobial/steroid/antifungal proprietary preparations. When ear 
cytology indicated overgrowth Malassezia spp. 100 mg oral ketoconazole (Nizoral, Janssen-Cilag, 
Auckland, NZ) was prescribed. A good response was obtained to the treatments although signs 
recurred after variable intervals. 
Mucocutaneous pyoderma became a major feature in late 2013 and did not resolve following several 
courses of oral cephalexin, each >2 weeks in duration, over several months. Culture of the nasal 
exudate in January 2014 revealed a S. intermedius group isolate that was sensitive to oxacillin, 
cephalothin, erythromycin, tetracycline, clindamycin, enrofloxacin and trimethoprin/sulpha. The 




The dog appeared well on presentation at the Allergy and Dermatology Clinic on the 2 May 2014. 
The owner reported good exercise tolerance, normal appetence, consistent weight and unchanged 
water intake. 
On examination, a yellow mucoid exudate was present about both nares which were crusted dorsally. 
The lower lips were crusted with haemopurulent exudate. Epidermal collarettes were present on the 
trunk with more lesions dorsally and laterally than ventrally. There were peri-anal crusts. Mild 
erythema was present on the concave aspect of both pinnae. The feet were normal. Peripheral lymph 
nodes were normal size. 
Cytology, performed on the nasal exudate and skin lesions, revealed neutrophils and numerous cocci. 
Red blood cells were also present in exudate from the lower lip lesions. Trichograms involving 
approximately 200 hair shafts were negative for Demodex mites. 
A diagnosis of mucocutaneous pyoderma, superficial spreading pyoderma and focal deep pyoderma 
was made. Interim treatment was 100 mg cefpodoxime (Simplicef, Zoetis, Auckland, NZ) given 
orally once per day. 
 
Microbiological findings 
Staphylococcus pseudintermedius was isolated from the nasal exudate. Colony morphology, when 
cultured aerobically on blood agar was typical for staphylococci. The colonies were catalase-positive, 
DNase-positive, hyaluronidase-negative and polymyxin B-sensitive, indicating 
a Staphylococcus species from the intermedius group. Identification as S. pseudintermedius was 
performed using matrix-assisted laser desorption ionisation-time of flight mass spectrometry 
(MALDI-TOF-MS) (Decristophoris et al. 2011), using a Bruker Daltonik GmbH microflex, version 
1.3 (Bruker Daltonik GmbH, Bremen, Germany) with the dervied spectra compared to a validated 
reference database (Maldi biotyper version 3.1; Bruker Daltonik GmbH). 
Antimicrobial susceptibility testing was performed using Kirby-Bauer disc diffusion. Zone diameters 
were interpreted according to the Clinical Laboratory Standards Institute (Anonymous 2008, 2010). 
The isolate was resistant to numerous antimicrobials including oxacillin (Table 1). Resistance to 
oxacillin (a surrogate for methicillin) can sometimes occur in isolates without the mecA gene (Frank 
and Loeffler 2012), so the isolate was referred to the Institute of Environmental Science and Research 
(Porirua, NZ). The presence of the mecA gene was confirmed by PCR according to the method of 
Maes et al. (2002). 
Swabs of the owner's nose were collected by their medical practitioner and were negative for S. 
pseudintermedius when tested in a medical laboratory. Swabs of the nose, lips and anus of the other 
dog in the household were similarly negative when tested by Gribbles Veterinary Pathology 
(Hamilton, NZ). 
Genetic relatedness of the isolate to MRSP isolated in Western Australia (Siak et al. 2014) was 
determined using pulsed field gel electrophoresis (PFGE). The PFGE was carried out in the same 
laboratory and under the same conditions as described by Siak et al. (2014), and used SmaI (Roche 
Diagnostics, Auckland, NZ) and cfr91 (ThermoFisher Scientific, Scoresby, Victoria, Australia) 
restriction enzymes as described by Perreten et al. (2013). The pulse times were 5–40 seconds over 18 
hours and 20–25 seconds over 5 hours. Chromosomal patterns were examined visually and scanned 
with a Quality One device (Bio-Rad Laboratories Pty Ltd, Auckland, NZ). The unweighted pair group 
method with arithmetic mean was used to assess relatedness, with settings for tolerance and 
optimisation of 1.25% and 0.5%, respectively. Isolates with ≥80% similarity were considered the 
same pulsotype. The PFGE pulsotype of the isolate from the case described here was found not to be 
related to the Western Australian isolates, on the basis of <80% similarity. The latter strain was 
related to the internationally known sequence type (ST)68 (Siak et al.2014). 
 
Treatment 
Oral antimicrobial treatment was changed on the 10 May 2015 to 100 mg per day rifampicin (Rifadin, 
Aventis, Auckland, NZ) given orally for 2 weeks. The choice of rifampicin was based on the results 
of Kirby-Bauer sensitivity tests, the first author's 20-year experience of its use in deep pyoderma, its 
ability to achieve effective concentrations in neutrophils (Nielson and Black 1999)  and evidence that 





After the 2-week course of rifampicin, treatment with 100 mg per day cefpodoxime was initiated. A 
clinical response to the first 2 weeks of rifampicin treatment was observed, but the change to 
cefpodoxime resulted in exacerbation of the lesions after 1 week. The choice of cefpodixime was 
based on the intermediate Kirby-Bauer sensitivity to cefitoxin and was made before the PCR result 
was available. It was substituted on 13 June 2014 with approximately 13 mg/kg enrofloxacin (Baytril, 
Bayer NZ Ltd) given once daily. Toward the end of this phase of treatment, the nasal, skin and anal 
lesions had resolved although some crusting remained on the lower lips. 
Inappetance and lethargy were observed at this time and blood and urine tests were performed. The 
urine specific gravity was 1.047, with high protein concentrations and moderate blood present. A 
complete blood count showed a moderate anaemia that was strongly regenerative. Further urine 
testing showed a urine protein:creatinine ratio of 1.0 (>0.5 is considered consistent with renal 
disease). The dog collapsed the next day with a temperature of 41°C. Ultrasonographic examination 
detected an abnormality of one kidney. The owner declined further testing and requested euthanasia 
on 24 June 2014. Post-mortem examination was not permitted. 
 
Discussion 
Globally, infection with MRSP is a major clinical problem for dogs, owners and veterinarians. Clonal 
spread has been a feature in many regions with ST71 the most frequently identified clone in Europe 
and ST68 in North America (Perreten et al. 2010). In addition to mecA, most MRSP strains carry 
resistance genes to several different classes of antimicrobials (Perreten et al. 2010). 
While nosocomial infections do occur, transmission is primarily from asymptomatic carriers to 
infection-vulnerable dogs (Pinchbeck et al). Dogs may be colonised by MRSP for >12 months after 
infection (Windahl et al. 2012). MRSP does not appear to be more virulent than methicillin-
susceptible S. pseudintermedius. Treatment of MRSP carriers is not recommended in countries where 
MRSP has become established. (Frank and Loeffler 2012). However in countries with low MRSP 
prevalence, decolonisation treatment may be a reasonable strategy to limit its transmission. 
Strategies need to be adapted to particular environments to prevent the transmission of MRSP in low 
prevalence countries. In New Zealand there are many opportunities for dogs to interact freely; dog 
competitions, day-care facilities and boarding kennels all present particular risks for exchange of S. 
pseudintermedius. Veterinary clinics are a risk because they will have more infection-vulnerable dogs 
than in the wider environment. Preventive measures may include scheduling appointments at 
veterinary clinics for pyoderma-affected dogs distant from debilitated or pyoderma-prone dogs, in 
addition to hygiene measures within the facility. 
Because MRSP is frequently multidrug resistant, treatment of MRSP-associated pyoderma can be 
difficult. For this reason it would seem reasonable for an island nation to create barriers to the 
importation of overseas clones that have spread epidemically. In the case described here the organism 
was not detected in the carriage sites of the owner or companion dog, and no further MRSP were 
isolated in the following 15 months (C. Douglass, unpublished data), suggesting that this isolate was 
unlikely to be a successful clone. One major veterinary pathology laboratory in New Zealand has been 
using oxacillin Kirby-Bauer discs routinely for >2 years (C. Douglass, unpublished data) and the other 
reported no evidence of multidrug resistant S. pseudintermedius (G. D'Amours, pers. Comm1. It is 
unlikely that successful MRSP clones are present in New Zealand currently. This contention is 
supported by data from both laboratories which together culture approximately 60 S. 
intermedius group isolates weekly. 
Identification of this single MRSP isolate over a 2-year period contrasts with the dramatic emergence 
of MRSP in dogs internationally (Beck et al. 2012). The emergence of MRSP in Australia is typified 
by the experience of a dermatology referral practice in Melbourne which first isolated a canine MRSP 
in May 2013 and subsequently recorded 95 cases in a 3-month period in late 2014 (Robson 2015). 
The history of New Zealand having predominantly international strains of MRSA (Heffernan and 
Bakker 2011), rather than local strains, and the finding that international travel plays a significant role 
in transmission of MRSA with carrier or infected humans (Zhou et al. 2014) would support the use of 
border controls to detect dogs carrying MRSP. 
The unavailability of oral chloramphenicol in New Zealand limits the choice of antimicrobials for 
treating MRSP infections. Although rifampicin and enrofloxacin were effective in this dog, rifampicin 
is difficult to use because of potential hepatotoxicity and both rifampicin and fluoroquinalones have 
been associated with the emergence of antimicrobial resistance. Topical antimicrobials used with 
shampoos have also been shown to be useful but resistance to some topical antimicrobials has been 
reported, and topical treatment of deep pyoderma is considered adjunctive rather than primary 
(Miller et al. 2013). 
The detection of MRSP in New Zealand is a public health concern, and should prompt increased 
vigilance in assessing response to antimicrobial treatment of canine pyoderma and the use of 
microbiological investigation, including susceptibility testing to oxacillin when response is doubtful. 
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Table 1. Results for antimicrobial susceptibility, determined using Kirby-Bauer disc diffusion, of an 
isolate of Staphylococcus pseudintermedius from the nasal exudate of a Sealyham terrier dog 









Amoxicillin/clavulanic acid 30 Resistant 
Cephalothin 30 Intermediate 
Erythromycin 15 Resistant 
Oxacillin 1 Resistant 
Penicillin 10 Resistant 
Tetracycline 30 Resistant 
Clindamycin 2 Resistant 
Enrofloxacin 5 Sensitive 
Trimethoprim/sulphonamide 25 Resistant 
Rifampicin 5 Sensitive 
Mupirocin 5 Sensitive 
 
 
 
 
 
 
 
